A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Item 1. Business We are a commercial-stage company that develops and sells high performance water solutions to the medical and commercial markets. In medical markets, we sell water filtration products. Our medical water filters, mostly classified as ultrafilters, are used primarily by hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate. Because our ultrafilters capture contaminants as small as 0.005 microns in size, they minimize exposure to a wide variety of bacteria, viruses, fungi, parasites, and endotoxins. In commercial markets, we manufacture and sell water filters that improve the taste and odor of water and reduce biofilm, bacteria, heavy metals, chemical compounds, scale build-up in downstream equipment, and other various contaminants.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 18M | 14M | 14M | 10.0M | 10M | 8.6M |
| Net Income | 0 | 74K | -1.6M | -7.4M | -4.1M | -4.8M |
| EPS | $0.14 | $0.01 | $-0.15 | $-0.73 | $-0.41 | $-0.52 |
| Free Cash Flow | 0 | -547K | 752K | -3.4M | -1.5M | -7.1M |
| ROIC | 8.6% | 0.9% | -18.8% | -31.1% | -34.8% | -37.0% |
| Gross Margin | 63.2% | 61.6% | 59.0% | 47.4% | 55.1% | 57.4% |
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.04 | 0.05 | 0.07 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 1.4M | 6K | -1.6M | -4.3M | -3.3M | -4.3M |
| Operating Margin | 8.1% | 0.0% | -11.2% | -43.5% | -31.8% | -49.9% |
| ROE | 0.0% | 0.9% | -18.8% | -132.0% | -35.1% | -38.1% |
| Shares Outstanding | 11M | 7M | 11M | 10M | 10M | 9M |
NEPHROS INC passes 2 of 9 quality checks, indicating weak fundamentals.
NEPHROS INC trades at 288.0x trailing earnings, compared to its 15-year median P/E of 15.0x, suggesting it is currently Expensive relative to its historical range. The company's 5-year average gross margin is 56.1%. At current prices, the estimated annualized return to fair value is -12.1%.
NEPHROS INC (NEPH) has a current P/E ratio of 288.0, compared to its historical median P/E of 15.0. The stock is currently considered Expensive based on its historical valuation range.
NEPHROS INC (NEPH) has a 5-year average return on invested capital (ROIC) of -24.2%. This is below average and may indicate limited pricing power.
NEPHROS INC (NEPH) has a market capitalization of $31M. It is classified as a small-cap stock.
NEPHROS INC (NEPH) does not currently pay a regular dividend.
Based on historical P/E analysis, NEPHROS INC (NEPH) appears expensive. The current P/E of 288.0 is 1820% above its historical median of 15.0.
NEPHROS INC (NEPH) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
NEPHROS INC (NEPH) reported annual revenue of $14 million in its most recent fiscal year, based on SEC EDGAR filings.
NEPHROS INC (NEPH) has a net profit margin of 0.5%. This is a modest margin.
NEPHROS INC (NEPH) generated $-547 thousand in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
NEPHROS INC (NEPH) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
NEPHROS INC (NEPH) reported earnings per share (EPS) of $0.01 in its most recent fiscal year.
NEPHROS INC (NEPH) has a return on equity (ROE) of 0.9%. This indicates moderate shareholder returns.
NEPHROS INC (NEPH) has a 5-year average gross margin of 56.1%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for NEPHROS INC (NEPH), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
NEPHROS INC (NEPH) has a book value per share of $1.16, based on its most recent annual SEC filing.